Pretreatment HIF-1α and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer

Anticancer Research

Volumn 31, Issue 5, 2011, Pages 1559-1565

  Havelund, Birgitte Mayland ^a   Sørensen, Flemming Brandt ^a   Lindebjerg, Jan ^a   Spindler, Karen Lise Garm ^a   Jakobsen, Anders ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

Glucose transporter 1; Hypoxia; Hypoxia inducible factor 1 ; Preoperative chemoradiotherapy; Rectal cancer

Indexed keywords

FOLINATE CALCIUM; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UFT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RECTUM CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; RECTAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79958092110     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
2. Hockel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001. (Pubitemid 32219813)
3. Vordermark D and Brown JM: Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 179: 801-811, 2003.
4. 2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
5. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH and Gassmann M: Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J 15: 1312-1314, 2001.
6. Greijer AE, is-van Diemen PM, Fijneman RJ, Giles RH, Voest EE, van HV and Meijer GA: Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Arch 452: 535-544, 2008.
7. Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, Kantsevoy SV and Dang LH: Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 66: 1684-1693, 2006. (Pubitemid 43259953)
8. Airley RE and Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53: 233-256, 2007. (Pubitemid 47074647)
9. Younes M, Lechago LV, Somoano JR, Mosharaf M and Lechago J: Wide expression of the human erythrocyte glucose transporter GLUT1 in human cancers. Cancer Res 56: 1164-1167, 1996.
10. Younes M, Lechago LV and Lechago J: Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 2: 1151-1154, 1996. (Pubitemid 26238445)
11. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
12. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A and Burstein DE: GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83: 34-40, 1998. (Pubitemid 28299626)
13. Eckert AW, Lautner MH, Taubert H, Schubert J and Bilkenroth U: Expression of GLUT-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep 20: 1381-1385, 2008.
14. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P and Semenza GL: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138-1143, 2003. (Pubitemid 36278449)
15. Theodoropoulos GE, Lazaris AC, Theodoropoulos VE, Papatheodosiou K, Gazouli M, Bramis J, Patsouris E and Panoussopoulos D: Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer. Int J Colorectal Dis 21: 248-257, 2006. (Pubitemid 43280332)
16. Rasheed S, Harris AL, Tekkis PP, Turley H, Silver A, McDonald PJ, Talbot IC, Glynne-Jones R, Northover JM and Guenther T: Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer 100: 1666-1673, 2009.
17. Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, Kinugasa S, Tachibana M and Nagasue N: Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 10: 8554-8560, 2004. (Pubitemid 40053424)
18. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS and Ogino S: HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 176: 2292-2301, 2010.
19. Furlan D, Sahnane N, Carnevali I, Cerutti R, Bertoni F, Kwee I, Uccella S, Bertolini V, Chiaravalli AM and Capella C: Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. Hum Pathol 39: 1483-1494, 2008.
20. Lu XG, Xing CG, Feng YZ, Chen J and Deng C: Clinical significance of immunohistochemical expression of hypoxia-inducible factor-1alpha as a prognostic marker in rectal adenocarcinoma. Clin Colorectal Cancer 5: 350-353, 2006. (Pubitemid 43280065)
21. Wendling P, Manz R, Thews G and Vaupel P: Heterogeneous oxygenation of rectal carcinomas in humans: a critical parameter for preoperative irradiation? Adv Exp Med Biol 180: 293-300, 1984.
22. Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De SH, Penninckx F, McBride WH, Begg AC and Haustermans KM: Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 65: 246-254, 2006.
23. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM and Wenger RH: The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220, 2003. (Pubitemid 36712933)
24. Moeller BJ and Dewhirst MW: HIF-1 and tumour radiosensitivity. Br J Cancer 95: 1-5, 2006.
25. Korkeila E, Jaakkola PM, Syrjanen K, Sundstrom J and Pyrhonen S: Preoperative radiotherapy down regulates the nuclear expression of hypoxia-inducible factor-1alpha in rectal cancer. Scand J Gastroenterol 45: 340-348, 2009.
26. Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier-Hayes DJ and Kay EW: GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int J Cancer 125: 2778-2782, 2009.
27. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH and Semenza GL: Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
28. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I and West C: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7: 928-934, 2001. (Pubitemid 32708731)
29. Burri P, Djonov V, Aebersold DM, Lindel K, Studer U, Altermatt HJ, Mazzucchelli L, Greiner RH and Gruber G: Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56: 494-501, 2003. (Pubitemid 36542909)
30. Mineta H, Miura K, Takebayashi S, Misawa K, Araki K, Misawa Y and Ueda Y: Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res 22: 3489-3494, 2002. (Pubitemid 36132817)
31. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P and Samama G: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73: 2680-2686, 1994. (Pubitemid 24166250)
32. Svanholm H, Starklint H, Gundersen HJ, Fabricius J, Barlebo H and Olsen S: Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. APMIS 97: 689-698, 1989. (Pubitemid 19217684)
33. Cooper R, Sarioglu S, Sokmen S, Fuzun M, Kupelioglu A, Valentine H, Gorken IB, Airley R and West C: Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 89: 870-876, 2003.
34. Atkin GK, Daley FM, Bourne S, Glynne-Jones R, Northover JM, and Wilson GD: The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery. Br J Cancer 95: 928-933, 2006. (Pubitemid 44498110)